Completed PHASE3 INTERVENTIONAL NCT00600626

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Comparison of Basal Bolus Treatment With Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes Mellitus

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2

Interventions biphasic insulin aspart insulin NPH insulin aspart

Updated 7 times since 2017 Last updated: Jan 5, 2017 Started: Jan 31, 2004 Primary completion: Jul 31, 2004 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00600626, this PHASE3 trial focuses on Diabetes and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

Phase: PHASE4 → PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Heilbrunn, Germany , Beverwijk, Netherlands , Bradford, United Kingdom , Brighton, United Kingdom , Cheras, Malaysia , Cluj-Napoca, Romania , Constanța, Romania , Coventry, United Kingdom , Córdoba, Spain , Delft, Netherlands and 42 more locations